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activated NK cells or chemotherapy in our mouse AMLmodel
systems. Importantly this GSK3 inhibition can be achieved
through a short ex vivo incubation of NK cells with a GSK3
inhibitor paving the way for a rapid implementation into a
clinical trial. Utilizing both in vitro studies with AML cell
lines (ex. OCI-AML3 and HL-60) and primary human AML
cells we observe approximately a 50% increase in efﬁcacy
with GSK3 inhibited NK cells as compared to untreated NK
cells. Further, we demonstrate signiﬁcant efﬁcacy of GSK3
inhibited NK cells in a mouse model of circulating human
AML. After 4 weekly injections of human NK cells, there is a
50% greater reduction in human AML cells present in the
mouse bone marrow with GSK3 inhibited NK cells as
compared to vehicle treated NK cells.
Besides efﬁcacy studies, our work has led a model of how
GSK3-inhibition enhances NK cell activity as depicted in
Figure 1. GSK3 inhibition leads to a dramatic increase in
adhesion of NK cells to target cells as demonstrated by a ﬂow
cytometric adhesion assay (49% vs 83% after 20 min
incubation) as well as live cell imaging. Consistent with the
increased adhesion, GSK3 inhibited NK cells as well as target
cells (after co-incubation) exhibit increased expression of
essential NK cell-target adhesion molecules including
L-selectin (on NK cells) and ICAM (on target cells). The
induction of ICAM on target cells is due to a marked
induction in TNFa production from the NK cells upon
incubation with target cells (>7 fold increase in TNFa
production). TNFa neutralization impairs the NK activity of
the GSK3 inhibited NK cells (w30%) but not vehicle treated
cells. Finally, GSK3 inhibition also leads to changes in the NK
cells that enhance activity such as increased expression ofFigure 1. Model of how GSK3 inhibition leads to hyperactive NK cells. GSK3I -
GSK3 inhibitor.granzyme and perforin and secretion of IFNg. Overall, our
work has a revealed a novel strategy for NK cell therapy that
holds high clinical potential.179
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease that destroys the motor neurons of the brain and
spinal cord. With no deﬁnitive therapy, most patients die
within 3-5 years of diagnosis. Extensive research is under-
way including the use of stem cells to regenerate damaged
neurons. Although typically an adult disease, childhood
cases are reported. Our patient began showing symptoms at
age 6 and was formally diagnosed with the rare juvenile
form of ALS at age 9. At consult, she displayed marked
spasticity with loss of ﬁnemotor control. She could not walk
or communicate verbally and required nocturnal ventila-
tory support. She was G-tube dependent for nutrition.
Because of her young age, she was ineligible for clinical
studies. After an ethics consult, FDA, IRB, and ﬁnancial ap-
provals, we followed Deda’s procedure (Cytotherapy
2009:11;18-15).
Methods, Intervention, & Analysis: Autologous, bone
marrow cells were harvested from iliac crests and
collected by Ficoll density gradient. The following day
laminectomy of C1 and partial laminectomy of C2 was
performed. A suspension of 6 million cells in 300 micro-
liters was prepared. After a 25 gauge needle was advanced
to a depth of 9 e 10 mm into the anterior horn of the
cervical spinal cord at a 20 degree angle, 500,000 cells/
50uL were injected. Six injections were performed on each
side of the midline (12 injections). Each injection was 7
mm apart on the mid-rostral caudal line and 2 mm off
midline to each other. Two strips of gel foam each infused
with 5 million cells/500uL were placed along the anterior
quadrant of the spinal cord prior to dural closure. An
additional 5 million cells/500uL were injected into the
subarachnoid space. The remainder of the cells were
injected intravenously (1.2 x 10e8 TNC/kg). There were no
postoperative complications.
Findings & Interpretation: Peak response was seen at 6
months with 12 month duration: improved phonation, facial
movements, swallowing, and upper extremity control.
Nocturnal CPAP use was successfully removed. She devel-
oped intermittent spasms/clonus with right upper extremity
pain. The patient refused additional ventilatory support and
with disease progression, died 25 months later of respiratory
failure.
Discussion & Implications: Additional studies are needed to
evaluate this therapy.
